Skip to content

Effects of different templates in transperineal systematic prostate biopsy on the detection rate and pathological stage upgrade of prostate cancer

Effects of different templates in transperineal systematic prostate biopsy on the detection rate and pathological stage upgrade of prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056386
Enrollment
Unknown
Registered
2022-02-04
Start date
2022-02-14
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

The new template group:Transitional zone tumor transitional zone 8 needles + peripheral band 4 needles
Peripheral zone tumor transitional zone 4 needles + peripheral band 8 needles
The old template group:Transitional zone 4 needles + peripheral band 8 needles
Targeted biopsy group:Targeted biopsy 3 needles

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
30 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Male; 2. Patients who plan to receive prostate biopsy for definite diagnosis due to elevated PSA, positive digital rectal examination or suspicious prostate cancer indicated by imaging; 3. Patients who volunteered to participate in the study after the existing diagnosis and treatment plan were informed.

Exclusion criteria

Exclusion criteria: 1. Patients who have previously received prostate puncture due to suspected prostate cancer; 2. Patients with metal implants and pacemakers in the body who cannot be detected by 3.0T MRI; 3. PSA > 100 ng/ml; 4. Concurrent with other serious systemic diseases, including severe respiratory, circulatory, nervous, mental, digestive, endocrine, immune, urinary and other system diseases, which the researcher believes may interfere with the treatment, evaluation and compliance of this study; Or other patients who have been determined by pre-anaesthetic assessment to be unable to tolerate general anesthesia; 5. Patients who are participating in other clinical trials or have participated in other clinical trials less than 1 year after completion; 6. Patients deemed unsuitable to participate in the clinical trial by the investigator.

Design outcomes

Primary

MeasureTime frame
biopsy pathology;

Secondary

MeasureTime frame
clinical stage;biopsy needles;prostate imaging reporting and data system;prostate specific antigen;

Countries

China

Contacts

Public ContactHuang Yuhua, Wei Xuedong

The First Affiliated Hospital of Soochow University

sdfyyhyh@163.com86 512 67972184

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026